Earnings ·
Century Therapeutics, Inc. reported financial results for the quarter ended June 30, 2026, announcing a net loss of…
IPSCCentury Therapeutics, Inc.
Century Therapeutics, Inc. reported financial results for the quarter ended June 30, 2026, announcing a net loss of $34.6 million and cash reserves of $197.2 million as of June 30, 2026, providing an estimated operating runway into the first quarter of 2029. The company completed a pre-IND meeting with the FDA for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, aligning on nonclinical data and trial design while maintaining an IND submission target for the fourth quarter of 2026. Additionally, Century remains on track to initiate clinical trials in 2026 for CNTY-308, a CD19-targeted CAR-iT cell therapy for B-cell-mediated autoimmune diseases. The biotechnology company develops induced pluripotent stem cell-derived therapies for autoimmune diseases and cancer.